| Literature DB >> 31212583 |
Byeoung-Kyu Choi1,2, Phan Thi Hoai Trinh3,4, Hwa-Sun Lee5, Byeong-Woo Choi6, Jong Soon Kang7, Ngo Thi Duy Ngoc8, Tran Thi Thanh Van9,10, Hee Jae Shin11,12.
Abstract
Five new sesterterpenes, 14,15-dehydro-6-epi-ophiobolin K (1), 14,15-dehydro- ophiobolin K (2), 14,15-dehydro-6-epi-ophiobolin G (3), 14,15-dehydro-ophiobolin G (4) and 14,15-dehydro-(Z)-14-ophiobolin G (5), together with four known ophiobolins (6-9) were isolated from the marine fungus Aspergillus flocculosus derived from the seaweed Padina sp. collected in Vietnam. The five new ophiobolins were first isolated as ophiobolin derivatives consisting of a fully unsaturated side chain. Their structures were elucidated via spectroscopic methods including 1D, 2D NMR and HR-ESIMS. The absolute configurations were determined by the comparison of chemical shifts and optical rotation values with those of known ophiobolins. All compounds (1-9) were then evaluated for their cytotoxicity against six cancer cell lines, HCT-15, NUGC-3, NCI-H23, ACHN, PC-3 and MDA-MB-231. All the compounds showed potent cytotoxicity with GI50 values ranging from 0.14 to 2.01 μM.Entities:
Keywords: Aspergillus flocculosus; anti-proliferation; marine fungus; ophiobolins
Year: 2019 PMID: 31212583 PMCID: PMC6628216 DOI: 10.3390/md17060346
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of 1–9 isolated from Aspergillus flocculosus.
1H and 13C NMR data for 1, 2 and 3 at 600 MHz (δ in ppm, J in Hz).
| Position | 1 a | 2 b | 3 b | 4 b | 5 b |
|---|---|---|---|---|---|
| 1α | 1.63, m | 1.54, m | 1.22 (t, 13.2) | 1.44, m | 1.42, m |
| 1β | 1.84, m | 1.54, m | 2.15 (dd, 13.2, 3.6) | 2.13 (dd, 15.8, 4.5) | 2.13 (dd, 15.8, 4.5) |
| 2 | 2.19, m | 2.57, m | 2.72 (d, 12.9) | 3.32, overlap | 3.31, overlap |
| 4 | 2.47 (d, 16.6) | 2.57 (d, 18.9) | 6.01, s | 6.09, s | 6.08, s |
| 3.15 (d, 16.6) | 2.70 (d, 18.9) | ||||
| 6 | 3.33 (d, 10.5) | 3.47 (d, 11.8) | 3.53 (d, 3.6) | 4.29 (d, 7.2) | 4.28 (d, 7.2) |
| 8 | 6.84 (d, 6.7) | 7.44 (t, 8.6) | 6.91 (dd, 6.2, 2.3) | 7.24 (d, 6.7) | 7.21 (d, 6.8) |
| 9α | 2.94 (d, 20.8) | 2.48, m | 3.02 (d, 21.3) | 2.37, m | 2.30, m |
| 9β | 2.22, m | 2.48, m | 2.31, m | 2.37, m | 2.22, m |
| 10 | 3.19 (d, 13.0) | 2.28, m | 3.37 (d, 13.1) | 3.03 (d, 16.5) | 3.06 (d, 16.5) |
| 12α | 1.50, m | 1.43, m | 1.45, m | 1.46, m | 1.44, m |
| 12β | 1.63, m | 1.86, m | 1.65, m | 1.46, m | 1.44, m |
| 13α | 2.25 (dd, 14.8, 6.3) | 2.48, m | 2.31, m | 2.40, m | 2.37, m |
| 13β | 2.59, m | 2.95, m | 2.58 (dd, 14.8, 6.4) | 3.08, m | 3.03, m |
| 16 | 6.42 (d, 15.3) | 6.37 (d, 15.1) | 6.43 (d, 15.3) | 6.31 (d, 15.3) | 6.14 (d, 15.1) |
| 17 | 6.38 (dd, 15.3, 9.7) | 6.39 (dd, 15.1, 10.1) | 6.40(dd, 15.3, 9.3) | 6.34 (dd, 15.3, 10.3) | 6.31 (dd, 15.1, 10.5) |
| 18 | 5.93 (d, 9.7) | 5.92 (d, 10.1) | 5.90 (d, 9.3) | 5.88 (d, 10.3) | 5.94 (d, 10.5) |
| 20 | 1.47, s | 1.37, s | 2.12, s | 2.29, s | 2.27, s |
| 21 | 9.23, s | 9.28, s | 9.25, s | 9.46, s | 9.44, s |
| 22 | 0.94, s | 1.05, s | 0.99, s | 0.86, s | 0.84, s |
| 23 | 1.83, s | 1.96, s | 1.83, s | 1.72, s | 1.72, s |
| 24 | 1.81, s | 1.81, s | 1.78, s | 1.79, s | 1.77, s |
| 25 | 1.79, s | 1.81, s | 1.79, s | 1.80, s | 1.80, s |
The assignments were aided by COSY, NOESY, HSQC, and HMBC NMR spectra. a Measured in CDCl3; b Measured in methanol-d4.
13C NMR data for 1–5 at 150 MHz (δ in ppm).
| Position | 1 a | 2 b | 3 b | 4 b | 5 b |
|---|---|---|---|---|---|
| 1 | 41.4 | 41.5 | 45.3 | 34.9 | 34.9 |
| 2 | 49.6 | 50.6 | 49.5 | 49.8 | 49.9 |
| 3 | 76.7 | 76.6 | 179.9 | 180.2 | 180.2 |
| 4 | 55.0 | 53.9 | 129.4 | 130.1 | 130.1 |
| 5 | 216.6 | 216.2 | 209.4 | 209.2 | 209.4 |
| 6 | 48.8 | 48.8 | 49.7 | 48.0 | 48.0 |
| 7 | 142.1 | 141.8 | 140.6 | 138.7 | 138.6 |
| 8 | 158.4 | 160.7 | 156.7 | 159.7 | 160.0 |
| 9 | 34.1 | 29.3 | 34.0 | 28.8 | 29.9 |
| 10 | 47.8 | 56.2 | 47.2 | 41.9 | 40.7 |
| 11 | 43.6 | 44.2 | 44.0 | 45.1 | 45.3 |
| 12 | 44.5 | 34.9 | 43.4 | 40.4 | 40.4 |
| 13 | 27.2 | 26.9 | 26.8 | 31.4 | 33.1 |
| 14 | 146.8 | 143.3 | 146.6 | 143.2 | 142.7 |
| 15 | 124.9 | 126.5 | 125.0 | 127.1 | 126.6 |
| 16 | 130.6 | 131.1 | 130.6 | 130.0 | 129.6 |
| 17 | 123.6 | 122.7 | 123.2 | 122.9 | 123.9 |
| 18 | 125.9 | 126.0 | 126.0 | 126.0 | 126.1 |
| 19 | 134.9 | 133.7 | 133.5 | 133.6 | 133.8 |
| 20 | 25.8 | 24.4 | 15.7 | 17.2 | 17.1 |
| 21 | 194.0 | 195.1 | 193.2 | 195.1 | 195.2 |
| 22 | 21.3 | 18.0 | 19.8 | 24.6 | 24.7 |
| 23 | 13.6 | 14.1 | 13.8 | 14.2 | 15.5 |
| 24 | 18.4 | 16.9 | 16.9 | 16.9 | 16.9 |
| 25 | 26.1 | 24.8 | 24.8 | 24.8 | 24.8 |
a Measured in CDCl3; b Measured in methanol-d4.
Figure 2Key COSY and HMBC correlations of 1 and 3.
Figure 3(a) Key NOESY correlations of 1 and 2. (b) Comparison of chemical shifts of H2-4 and H-6 in 1 (H-6α), 2 (H-6β), 6 (H-6α) and 7 (H-6β).
Figure 4Key NOESY correlations of 3–5.
Growth Inhibition (GI50, μM) Values of 1–9 against Human Tumor Cell Lines.
| Cell Lines a | GI50 (μM) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ADR b | |
| HCT-15 | 0.21 | 0.44 | 0.96 | 1.24 | 1.67 | 0.24 | 0.21 | 0.30 | 0.22 | 0.13 |
| NUGC-3 | 0.19 | 0.50 | 0.88 | 1.07 | 1.53 | 0.22 | 0.20 | 0.22 | 0.20 | 0.15 |
| NCI-H23 | 0.18 | 0.61 | 1.40 | 1.50 | 1.84 | 0.24 | 0.16 | 0.22 | 0.22 | 0.15 |
| ACHN | 0.24 | 0.53 | 1.14 | 1.40 | 2.01 | 0.43 | 0.20 | 0.23 | 0.42 | 0.16 |
| PC-3 | 0.24 | 0.47 | 1.00 | 1.38 | 1.60 | 0.27 | 0.36 | 0.20 | 0.20 | 0.14 |
| MDA-MB-231 | 0.14 | 0.63 | 1.05 | 1.35 | 1.75 | 0.19 | 0.22 | 0.21 | 0.19 | 0.15 |
a HCT-15: Colon cancer, NUGC-3: Stomach cancer, NCI-H23: Lung cancer, ACHN: Renal cancer, PC-3: Prostate cancer, MDA-MB-231: Breast cancer; GI50 values are the concentration corresponding to 50% growth inhibition. b ADR: Adriamycin as standard.